Neoprobe Corporation (NYSE Amex: NEOP) today announced that Dr. Mark
Pykett, President and Chief Executive Officer, will participate at the
Oppenheimer & Co. 22nd Annual Healthcare Conference. Dr.
Pykett will provide an update of the Company and its development
programs followed by a question and answer period with institutional
investors on December 13, 2011 at 10:50 AM EST in New York City.
Neoprobe Corporation (NYSE Amex: NEOP) is a biomedical company focused
on the development and commercialization of precision diagnostics and
radiopharmaceutical agents. Neoprobe is actively developing two
radiopharmaceutical agent platforms – Lymphoseek® and RIGScanTM
CR – to help identify the sites and pathways of undetected disease and
enable better diagnostic accuracy, clinical decision-making and
ultimately patient care. Neoprobe’s strategy is to deliver superior
growth and shareholder return by bringing to market novel
radiopharmaceutical agents and advancing the Company’s pipeline through
selective acquisitions, global partnering and commercialization efforts.
For more information, please visit www.neoprobe.com.